Alternative splicing acts as an independent prognosticator in ovarian carcinoma

Sci Rep. 2021 May 17;11(1):10413. doi: 10.1038/s41598-021-89778-0.

Abstract

Alternative splicing (AS) events associated with oncogenic processes present anomalous perturbations in many cancers, including ovarian carcinoma. There are no reliable features to predict survival outcomes for ovarian cancer patients. In this study, comprehensive profiling of AS events was conducted by integrating AS data and clinical information of ovarian serous cystadenocarcinoma (OV). Survival-related AS events were identified by Univariate Cox regression analysis. Then, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis were used to construct the prognostic signatures within each AS type. Furthermore, we established a splicing-related network to reveal the potential regulatory mechanisms between splicing factors and candidate AS events. A total of 730 AS events were identified as survival-associated splicing events, and the final prognostic signature based on all seven types of AS events could serve as an independent prognostic indicator and had powerful efficiency in distinguishing patient outcomes. In addition, survival-related AS events might be involved in tumor-related pathways including base excision repair and pyrimidine metabolism pathways, and some splicing factors might be correlated with prognosis-related AS events, including SPEN, SF3B5, RNPC3, LUC7L3, SRSF11 and PRPF38B. Our study constructs an independent prognostic signature for predicting ovarian cancer patients' survival outcome and contributes to elucidating the underlying mechanism of AS in tumor development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alternative Splicing*
  • Biomarkers, Tumor / genetics*
  • Carcinogenesis / genetics
  • Cystadenocarcinoma, Serous / genetics
  • Cystadenocarcinoma, Serous / mortality*
  • Datasets as Topic
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / mortality*
  • Prognosis
  • RNA Splicing Factors
  • RNA-Seq
  • Risk Assessment / methods
  • Survival Analysis

Substances

  • Biomarkers, Tumor
  • RNA Splicing Factors